XSNX (Novaccess Global) Other Stockholders Equity: $5.37 Mil (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSNX Novaccess Global Inc XSNX
12 GF Score
Price $0.00
View Full Analysis

What is Novaccess Global Other Stockholders Equity?

Novaccess Global XSNX 12 Other Stockholders Equity is $5.37 Mil as of Sep. 2024. GuruFocus rates XSNX with a GF Score™ of 12/100.

Novaccess Global's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $5.37 Mil.

Novaccess Global's quarterly Other Stockholders Equity increased from Mar. 2024 ($5.37 Mil) to Jun. 2024 ($5.43 Mil) but then declined from Jun. 2024 ($5.43 Mil) to Sep. 2024 ($5.37 Mil).

Novaccess Global's annual Other Stockholders Equity increased from Sep. 2022 ($4.21 Mil) to Sep. 2023 ($5.34 Mil) and increased from Sep. 2023 ($5.34 Mil) to Sep. 2024 ($5.37 Mil).

Novaccess Global Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Novaccess Global's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novaccess Global Other Stockholders Equity Chart

Novaccess Global Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.21 4.21 4.21 5.34 5.37

Novaccess Global Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.34 5.37 5.37 5.43 5.37
XSNX
12GF Score
Novaccess Global Inc XSNX
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novaccess Global Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $5.37 Mil mean?
Novaccess Global (XSNX) has a Other Stockholders Equity of $5.37 Mil as of Sep. 2024. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novaccess Global and its competitors.
Is Novaccess Global's Other Stockholders Equity too high?
Novaccess Global's current Other Stockholders Equity is $5.37 Mil. Overall, Novaccess Global has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Novaccess Global's Other Stockholders Equity compare to NBIO and BTAX?
Novaccess Global's Other Stockholders Equity of $5.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novaccess Global and its competitors. Novaccess Global's current Other Stockholders Equity is $5.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novaccess Global stock overvalued right now?
Novaccess Global (XSNX) has a current Other Stockholders Equity of $5.37 Mil. The current Other Stockholders Equity is $5.37 Mil. Novaccess Global's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Novaccess Global (XSNX), the current Other Stockholders Equity is $5.37 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novaccess Global Business Description

Address 459 Columbus Avenue, No. 607, New York, NY, USA, 10024
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.
12GF Score

Get the complete analysis for XSNX

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price